title: Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor             effect of cisplatin in non-small cell lung cancer xenografts.
abstract: RNA targeting the murine vascular endothelial growth factor receptor 2 (VEGFR2)             gene was designed and validated for efficient and robust silencing in vitro and             was delivered by polyethylenimines (PEI) in vivo to investigate the antitumor             effect on non-small cell lung cancer (NSCLC) xenografts. The following dosage             regimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA,             epidermal growth factor receptor (EGFR) siRNA, VEGFR2 siRNA+EGFR siRNA, cisplatin             alone and VEGFR2 siRNA+ EGFR siRNA+cisplatin. Targeted silencing of both VEGFR2             and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively             inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts.             These results suggest that combination therapy using siRNAs and chemotherapy agents             might offer a novel strategy for cancer treatment in the future.
authors.affiliation: Department of Pharmaceutical Science, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China.
authors.forename: Shan
authors.initials: S
authors.lastname: Chen
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Liu
authors.forename: Wenfei
authors.initials: W
authors.lastname: Gong
authors.forename: Huan
authors.initials: H
authors.lastname: Yang
authors.forename: Daofei
authors.initials: D
authors.lastname: Luo
authors.forename: Xialin
authors.initials: X
authors.lastname: Zuo
authors.forename: Wenshi
authors.initials: W
authors.lastname: Li
authors.forename: Ping
authors.initials: P
authors.lastname: Wu
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Qian
authors.initials: Q
authors.lastname: Xu
authors.forename: Aimin
authors.initials: A
authors.lastname: Ji
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology*; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D040301:Vascular Endothelial Growth Factor Receptor-2; D002945:Cisplatin